Plain language summary of isatuximab plus carfilzomib, lenalidomide, and dexamethasone for the treatment of people with high-risk newly diagnosed multiple myeloma.

IF 3 4区 医学 Q2 ONCOLOGY Future oncology Pub Date : 2024-09-30 DOI:10.1080/14796694.2024.2402639
Lisa B Leypoldt, Diana Tichy, Britta Besemer, Mathias Hanel, Marc S Raab, Christoph Mann, Markus Munder, Hans Christian Reinhardt, Axel Nogai, Martin Gorner, Yon-Dschun Ko, Maike de Wit, Hans Salwender, Christof Scheid, Ullrich Graeven, Rudolf Peceny, Peter Staib, Annette Dieing, Hermann Einsele, Anna Jauch, Michael Hundemer, Manola Zago, Ema Pozek, Axel Benner, Carsten Bokemeyer, Hartmut Goldschmidt, Katja C Weisel
{"title":"Plain language summary of isatuximab plus carfilzomib, lenalidomide, and dexamethasone for the treatment of people with high-risk newly diagnosed multiple myeloma.","authors":"Lisa B Leypoldt, Diana Tichy, Britta Besemer, Mathias Hanel, Marc S Raab, Christoph Mann, Markus Munder, Hans Christian Reinhardt, Axel Nogai, Martin Gorner, Yon-Dschun Ko, Maike de Wit, Hans Salwender, Christof Scheid, Ullrich Graeven, Rudolf Peceny, Peter Staib, Annette Dieing, Hermann Einsele, Anna Jauch, Michael Hundemer, Manola Zago, Ema Pozek, Axel Benner, Carsten Bokemeyer, Hartmut Goldschmidt, Katja C Weisel","doi":"10.1080/14796694.2024.2402639","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-15"},"PeriodicalIF":3.0000,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2024.2402639","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
关于伊沙妥昔单抗联合卡非佐米、来那度胺和地塞米松治疗高风险新诊断多发性骨髓瘤患者的纯文字摘要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Future oncology
Future oncology ONCOLOGY-
CiteScore
5.40
自引率
3.00%
发文量
335
审稿时长
4-8 weeks
期刊介绍: Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.
期刊最新文献
Comparative efficacy and safety of eribulin versus paclitaxel in breast cancer: a systematic review and meta-analysis. Multimodality high-frequency ultrasound in the evaluation of cervical malignant lymphoma before biopsy. Genetic variants in mitochondrial sirtuins associated with brain tumor risk: a case-control study. Physician preferences of biomarker testing strategies in newly diagnosed stage IV non-small cell lung cancer patients. Testosterone recovery post discontinuation of androgen deprivation for the treatment of advanced prostate cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1